STUDY DESIGN Dostarlimab in conjunction with carboplatin-paclitaxel (CP) has previously been shown to significantly improve progression-free survival (PFS) and overall survival (OS) outcomes compared with CP alone in patients with primary advanced or recurrent endometrial cancer (EC).1 This has led

STUDY DESIGN Niraparib is a potent and highly selective poly-ADP ribose polymerase (PARP) inhibitor.1 PARP inhibitors have shown a trend of favorable overall survival (OS) in platinum-sensitive recurrent ovarian cancer (PSROC) in the maintenance setting.1 However, this OS benefit appears inconsiste

Thrombocytosis is frequently observed among cancer patients and can be attributed to increased platelet production.1 While the underlying pathophysiology has not been completely elucidated, it is believed that platelet activation is essential for tumor progression due to the release of several plate

STUDY DESIGN For over 2 decades, locally advanced cervical cancer (LACC) has been treated with external beam radiotherapy (EBRT) and concurrent chemotherapy, followed by brachytherapy.1 However, the toxicity associated with these treatments along with the burden of the disease itself have led to a

Progression-free survival (PFS) is often utilized as an indicator of the overall survival (OS) of patients with endometrial cancer (EC) to facilitate regulatory approval for novel medical treatments.1 Nevertheless, its role as a surrogate marker for the survival outcomes of EC patients remains contr

The updated results from the DESTINY-Breast03 phase 3 trial showed that trastuzumab deruxtecan significantly prolonged progression-free survival (PFS) and overall survival (OS) among patients with human epidermal growth factor receptor 2-positive (HER2-positive) unresectable and/or metastatic breast

Approximately 50% of patients with metastatic castration-resistance prostate cancer (mCRPC) receive only 1 line of active therapy with a median survival of less than 2 years.¹ Hence, there is an urgent need to improve patient outcomes in the first-line mCRPC treatment setting.¹ In the PROpel phase 3 trial, the administration of olaparib and abiraterone combination in mCRPC patients, irrespective of homologous recombination repair gene mutation (HRRm) status, has achieved statistically significant and clinically meaningful improvements in radiographic progression-free survival (rPFS) than abiraterone monotherapy alone.